Nektar Therapeutics (NKTR) Tops Q3 EPS by 1c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $60.98 +0.10%
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
DTGI, CRMT, MAYS, More
EPS Growth %: +26.6%
Financial Fact:
Provision for income taxes: 139K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of ($0.19), $0.01 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $24.1 million versus the consensus estimate of $21.26 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
- Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
